logo evento
Madrid
26/27 Noviembre 2026

Program

Friday, 27 November
Previous Day
08:00 – 09:00
General assembly of the SLCG
09:00 – 10:15
SESSION VII: ADCs in lung cancer: are they already the present?
Chairs:
Dr. Margarita Majem Hospital de la Santa Creu i Sant Pau, Barcelona
Dr. Manuel Fernández Hospital Univ. de A Coruña
09:00 – 09:15
Development of ADCs
Dr. Marzia Del Re Saint Camillus International University, Rome (Italy)
09:15 – 09:30
ADCs in patients without targetable alterations
Dr. Andrés Barba Hospital de la Santa Creu i Sant Pau, Barcelona
09:30 – 09:45
Second-line ADCs after targeted therapy failure
Dr. Jon Zugazagoitia Hospital Univ. 12 de Octubre, Madrid
09:45 – 10:00
TROP-2: myths and facts
Dr. Yago Garitaonaindía National Center for Cancer Immune Therapy, Herlev (Denmark)
10:00 – 10:15
Discussion
10:15 – 11:20
SESSION VIII: Proffered posters
Chairs:
Dr. Bartomeu Massutí Hospital General Univ. Dr. Balmis, Alicante
Dr. Enric Carcereny ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona
10:15 – 11:15
Proffered posters presentation
11:15 – 11:20
Poster awards
11:20 – 11:50
Coffee break
11:50 – 13:15
SESSION IX: NSCLC targeted therapies I (Auditorium)
Chairs:
Dr. Javier de Castro Hospital Univ. La Paz, Madrid
Dr. Eider Azkona Hospital Univ. de Cruces, Barakaldo
11:50 – 12:05
First-line EGFR-mutant NSCLC: current standards and challenges
Dr. Ernest Nadal ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat, Barcelona
12:05 – 12:20
Uncommon EGFR mutations and exon 20 insertions
Dr. Paula Espinosa Hospital General Univ. de Valencia
12:20 – 12:35
Optimizing therapy in ALK-positive lung cancer
Dr. José Antonio López Hospital Univ. de Jaén
12:35 – 12:45
HER2-Mutant Lung Cancer: Present and Future of Precision Medicine
Dr. Mariola Blanco Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
12:45 – 13:00
Other targeted therapies: RET, ROS1, BRAF
Dr. Joaquim Bosch ICO, Hospital Univ. Dr. Josep Trueta, Girona
13:00 – 13:15
Discussion
11:50 – 12:50
SPECIAL SESSION: Nursing session (Newman meeting room)
Chairs:
Dr. Bartomeu Massutí Hospital General Univ. Dr. Balmis, Alicante
Dr. Jorgina Serra Hospital de la Santa Creu i Sant Pau, Barcelona
11:50 – 12:05
Follow-up of patients on treatment
Ms. Cristina Subirana Hospital Univ. de Bellvitge, Barcelona
12:05 – 12:20
Organization of the outpatient day hospital
Ms. Mª Dolores Pérez Hospital Univ. 12 de Octubre, Madrid
12:20 – 12:35
The role of nursing in long-term lung cancer survivors
Ms. Marta Méndez Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
12:35 – 12:50
Discussion
13:15 – 14:45
Lunch
13:15 – 14:45
Lunch Satellite Symposium (J. Maritain meeting room)Sponsored by AstraZeneca
14:45 – 16:00
SESSION X: NSCLC targeted therapies II
Chairs:
Dr. Antonio Calles Hospital General Univ. Gregorio Marañón, Madrid
Dr. Pilar Diz Hospital Univ. de León
14:45 – 15:00
KRAS G12C
Dr. Rafael López Hospital Clínico Univ. de Valladolid
15:00 – 15:15
KRAS: moving beyond G12C
Dr. Martín Lázaro Complejo Hospitalario Univ. de Vigo
15:15 – 15:30
MET
Dr. Virginia Calvo Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
15:30 – 15:45
Resistance mechanisms and second-line treatment strategies
Dr. Natasha Leighl Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Canada
15:45 – 16:00
Discussion
16:00 – 17:15
SESSION XI: Advances in small cell lung cancer
Chairs:
Dr. Manuel Dómine Hospital Univ. Fundación Jiménez Díaz, Madrid
Dr. Juan Luis Martí Hospital General Univ. Dr. Balmis, Alicante
16:00 – 16:15
Novel therapeutic strategies in limited-stage disease
Dr. Reyes Bernabé Hospital Univ. Virgen del Rocío, Sevilla
16:15 – 16:30
Novel strategies in extensive-stage disease: beyond DLL3
Dr. Edurne Arriola Hospital del Mar, Barcelona
16:30 – 16:45
Re-evaluating the place of RT in SCLC: is it time for a change?
Dr. Amelia Insa Hospital Clínico Univ. de Valencia
16:45 – 17:00
DLL3: changing the natural history of SCLC?
Dr. Noemí Reguart Hospital Clinic Barcelona
17:00 – 17:15
Discussion
17:15 – 17:30
Closing remarks
Previous Day